Treatment to Reduce Vascular Calcification in Hemodialysis Patients Using Vitamin K

Phase 2

Completed

• Conditions: Vascular Calcification; Complication of Hemodialysis; Systemic and Arterial Stiffness; Deficiency of Vitamin K2
• Interventions: Drug: menaquinone-7

• Registration Number: NCT02870829
• Lead Sponsor: National University Health System, Singapore

Brief Summary

The proposed study will seek to evaluate the prevalence and the progression of vascular calcification in a cohort of maintenance hemodialysis patients in Asian population. It will also evaluate the efficacy of vitamin K 2 supplementation in reducing the progression of vascular calcification in this group of patients.

This will be a single-center randomized, prospective and open-label interventional clinical trial of end stage renal failure patients on hemodialysis.Primary outcome will be absolute difference in coronary artery calcium (CAC) score at 18-month between control and intervention arms. Secondary outcomes will be to compare absolute difference in aortic valve calcification, percentage of patients with regression of coronary artery calcification of at least 10%, absolute difference in aortic and systemic arterial stiffness, mortality from any cause and major adverse cardiovascular events (MACE) over the same period.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-07
• Study First Submitted: 2016-08-14
• Study First Submitted QC: 2016-08-14
• Study First Posted: 2016-08-17
• Primary Completion: 2022-02
• Study Completion: 2022-02
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-13
• Last Update Posted: 2023-01-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 178

Inclusion Criteria

1. Age ≥ 45 years and less than 80 years
2. At least 12 months on Hemodialysis
3. Coronary artery calcium score of ≥ 30 in the baseline Multislice Computed Tomography
4. Able to give informed consent
5. Life expectancy of at least18 months

Exclusion Criteria

1. History of thrombosis in the last 6 months except vascular access thrombosis
2. Need for vitamin K antagonists therapy at baseline or in the 3 months prior to baseline
3. Presence of significant gut disease (inflammatory bowel disease, short-bowel syndrome)
4. Liver dysfunction
5. Alcohol or drug abuse
6. Presence of coronary stent or have undergone coronary artery bypass grafting
7. Women who are pregnant or breast feeding,
8. Those who are fearful of confined space and cannot lie still for Multislice Computed Tomography
9. Lack of safe contraceptive measures.
10. Those who had parathyroid surgery done.
11. Those with parathyroid hormone (PTH) > 150 pmol/l
12. Patient taking multivitamins containing vitamin K
13. Patient allergic to soy based products

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Vitamin K2	menaquinone-7	Vitamin K comes in various isoforms and we have elected to use the K2 isoform - menaquinone-7. We have chosen a dose of 360mcg 3x/week as previous studies using menaquinone-7 demonstrated an increasing dose efficacy relationship up to this strength. Vitamin K2 is manufactured by Nattopharma

Primary Outcome Measures

Name	Time	Method
Absolute difference in coronary artery calcium score at 18-month between control and intervention arms	18 months	Comparison made using the t-test following log transformation. Adjustment for baseline CAC scores made via the analysis of covariance.

Secondary Outcome Measures

Name	Time	Method
MACE defined as non-fatal myocardial infarction, heart failure, acute coronary syndrome, need for coronary revascularization, non-fatal stroke, significant peripheral vascular disease	18 months
Vascular access events, including clotting requiring insertion of a new dialysis catheter, declotting or exchange of an existing catheter, and vascular intervention during the study period	18 months
Mortality from any cause within the study period	18 months
Difference in plasma levels of dp-ucMGP at 18 months	18 months
Absolute difference in AVC score at 18-months	18 months	Comparison made using the t-test following log transformation. Adjustment for baseline AVC scores made via the analysis of covariance.
Percentage of patients with regression of CAC of ≥ 10% over 18-month	18 months
Absolute difference in cfPWV and AI at 18-months	18 months

Trial Locations

Locations (1)

National University Hospital; 🇸🇬 Singapore, Singapore